Recombinant human brain natriuretic peptide (Danhong Pharmaceutical)

重组人脑利钠肽 (山东丹红制药)

Report date: 2026/05/25 20:02:40

Base Information

Drug NameRecombinant human brain natriuretic peptide (Danhong Pharmaceutical)
Drug Alias NameBC003 (Danhong Pharmaceutical)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionNatriuretic peptide receptor 1 agonists
TargetsNatriuretic peptide receptor 1
Therapy Area/IndicationsAcutely decompensated congestive heart failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShandong Danhong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Danhong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAcutely decompensated congestive heart failure
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A